Medical Technology

@xconomy.com 3 years ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 3 years ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 4 years ago

Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug

@xconomy.com 4 years ago

MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests

@xconomy.com 4 years ago

Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More

@xconomy.com 4 years ago

After First Look at House Drug Plan, Stocks Rise Slightly

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing

@xconomy.com 4 years ago

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)